SYNGR1

SYNGR1 encodes a neuron-enriched integral membrane protein with four transmembrane domains that localizes to synaptic vesicles at axon terminals, where it participates in presynaptic vesicle biology. Three alternative transcripts (SYNGR1a, SYNGR1b, SYNGR1c) are generated from two promoters, with SYNGR1a being the predominant neuron-specific form; the protein is actively transported from neuronal somata to synaptic terminals, as evidenced by its enrichment at axon terminals relative to its mRNA distribution in the auditory brainstem (PMID:9760194, PMID:30664243). In non-neuronal glioblastoma cells, SYNGR1 overexpression suppresses lipid droplet accumulation and actin cytoskeleton remodeling by acting upstream of intracellular FGF1, as demonstrated by epistatic rescue with FGF1 overexpression (PMID:40478501). A nonsense mutation (Trp27Ter) in SYNGR1 was identified in a schizophrenia-affected family, implicating loss of SYNGR1 function in psychiatric disease (PMID:14732601).

1. 1998 High

   The gene structure, transmembrane topology, and neuron-specific expression pattern of SYNGR1 were established, defining it as a four-transmembrane-domain synaptic vesicle protein with three alternative transcript forms driven by two promoters.

   Evidence Genomic sequencing, EST database analysis, in situ hybridization, Northern blot, and RT-PCR in human CNS tissue

   PMID:9760194

   Open questions at the time

   • No direct demonstration of synaptic vesicle localization by immunogold or subcellular fractionation
   • Functional role of the protein on synaptic vesicles unknown
   • Functional differences among the three splice variants not tested
2. 2004 Medium

   A truncating nonsense mutation in SYNGR1 was linked to schizophrenia in a family study, providing the first genetic evidence that SYNGR1 loss-of-function may contribute to psychiatric disease.

   Evidence Sequencing of all SYNGR1 exons and splice junctions in a schizophrenia-affected family, with RT-PCR and Northern blot confirming brain expression of the affected transcript

   PMID:14732601

   Open questions at the time

   • No functional assay demonstrating that the truncated protein is non-functional or unstable
   • Association based on a single family; population-level replication absent
   • Mechanism linking SYNGR1 loss to schizophrenia pathophysiology not addressed
3. 2009 Low

   A missense variant (S26G) predicted to abolish a PKC phosphorylation site was identified in schizophrenia patients, raising the possibility that Ser26 phosphorylation regulates SYNGR1 function.

   Evidence Resequencing of SYNGR1 exons in schizophrenia cohort with in silico phosphorylation site prediction

   PMID:19641478

   Open questions at the time

   • No biochemical confirmation that Ser26 is phosphorylated by PKC in vitro or in vivo
   • Functional consequence of S26G on protein activity or trafficking not tested
   • Variant frequency and penetrance in larger cohorts not established
4. 2019 Medium

   Systematic proteomics-transcriptomics comparison across auditory brainstem regions demonstrated that SYNGR1 protein is actively transported to axon terminals, resolving how the protein reaches its site of action at the synapse despite somatic mRNA expression.

   Evidence DNA microarray transcriptomics and label-free mass spectrometry proteomics across rat auditory brainstem nuclei with correlation analysis

   PMID:30664243

   Open questions at the time

   • Active transport mechanism (motor proteins, vesicular carriers) not identified
   • Direct imaging of SYNGR1 trafficking in live neurons not performed
   • Whether transport is splice-variant-specific is unknown
5. 2025 Medium

   SYNGR1 was shown to suppress lipid droplet accumulation and actin remodeling in glioblastoma cells by downregulating intracellular FGF1, revealing a non-neuronal signaling axis with epistatic validation.

   Evidence Lentiviral overexpression of SYNGR1 and FGF1 in glioblastoma cells with rescue experiments, lipid droplet staining, RNA-seq, Western blot, and intracranial xenograft model with MRI

   PMID:40478501

   Open questions at the time

   • Molecular mechanism by which SYNGR1 downregulates FGF1 is unknown
   • Whether this lipid droplet/cytoskeleton axis operates in neurons is untested
   • Endogenous SYNGR1 loss-of-function phenotype in glioblastoma not examined

• The precise molecular function of SYNGR1 on synaptic vesicles — whether it acts as a transporter, scaffolding protein, or membrane organizer — remains unknown, and no direct binding partners on the vesicle have been identified.
• No interactome or co-immunoprecipitation studies identifying direct binding partners on synaptic vesicles
• No knockout or knockdown phenotype characterized in neurons
• No structural data from crystallography or cryo-EM